1. Home
  2. SOHU vs RAPT Comparison

SOHU vs RAPT Comparison

Compare SOHU & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sohu.com Limited

SOHU

Sohu.com Limited

HOLD

Current Price

$15.68

Market Cap

453.4M

Sector

Technology

ML Signal

HOLD

Logo RAPT Therapeutics Inc.

RAPT

RAPT Therapeutics Inc.

HOLD

Current Price

$34.24

Market Cap

498.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOHU
RAPT
Founded
1996
2015
Country
China
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
453.4M
498.4M
IPO Year
2000
2019

Fundamental Metrics

Financial Performance
Metric
SOHU
RAPT
Price
$15.68
$34.24
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
9
Target Price
$20.00
$57.00
AVG Volume (30 Days)
40.2K
412.1K
Earning Date
11-17-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
5.11
N/A
Revenue
$576,757,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$2.29
N/A
P/E Ratio
$3.06
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.79
$5.67
52 Week High
$16.45
$42.39

Technical Indicators

Market Signals
Indicator
SOHU
RAPT
Relative Strength Index (RSI) 57.48 65.62
Support Level $14.94 $30.00
Resistance Level $15.90 $35.10
Average True Range (ATR) 0.68 2.03
MACD 0.09 0.42
Stochastic Oscillator 80.60 84.06

Price Performance

Historical Comparison
SOHU
RAPT

About SOHU Sohu.com Limited

Sohu.com Ltd provides online media, games, and search products and services on PCs and mobile devices in China. The company operates in Sohu and Changyou segments. Sohu is an online media content and services provider. Through its social features, Sohu also enables users to generate and distribute content, as well as interact with each other on a platform. Changyou is an online game developer and operator. It generates maximum revenue from the Changyou segment.

About RAPT RAPT Therapeutics Inc.

RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Share on Social Networks: